Inclusion Criteria:

1. Patients must have histologically confirmed adenocarcinoma of the prostate.

2. Radiographic evidence of metastatic disease (Bone scan, CT(Computerized Tomography)
scan, or MRI(Magnetic Resonance Imaging) are acceptable) amenable to image-guided
biopsy.

3. Castrate levels of testosterone (testosterone <50 ng/dL) on androgen deprivation
therapy (ADT). LHRH(luteinizing hormone releasing hormone)agonist therapy must
continue while on study unless patient has previously undergone an orchiectomy.

4. The patient must have discontinued antiandrogens (bicalutamide, flutamide or
nilutamide) 30 days prior to baseline PSA.

5. Progression on at least one line of a prior docetaxel-based chemotherapy.

6. Patients must have adequate organ and marrow function as defined below:

- Absolute neutrophil count >1,500/μl

- Platelets >100,000/μl

- GFR(glomerular Filtration Rate) >30 ml/min

- ALT(Alanine transaminase) and AST(Aspartate transaminase) ≤ 2.5 X upper limit
of normal (ULN) or ≤ 5 X ULN in patients with liver metastasis

7. Age > 18 years

8. Ability to take oral medications (pills must be swallowed whole)

9. ECOG (Eastern Cooperative Oncology Group) performance status 0-2

10. Ability to understand and the willingness to sign a written informed consent document

11. Patients must be willing to undergo an image-guided biopsy of a metastatic site on at
least one occasion.

12. Patient agrees to utilize contraception while enrolled in the trial

Exclusion Criteria:

1. Patients who have received prior treatment with a platinum chemotherapy.

2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (requiring antifungal, antibiotic or antiviral therapy), history of
symptomatic congestive heart failure (NYHC (New York Heart Association
Classification) III), unstable angina pectoris, cardiac arrhythmia (uncontrolled
SVT(Super ventricular tachycardia)or any VT(ventricular tachycardia), or psychiatric
illness/social situations that would limit compliance with study requirements.

3. Patients with a medical contraindication to image-guided biopsies

4. Patients with a severe allergic reaction to satraplatin compounds.

5. Has a history of a prior malignancy with the exception of the following: adequately
treated basal cell or squamous cell skin cancer, or other cancers for which the
subject has been disease-free for at least 5 years.

6. Has had radiation therapy within 30 days prior to being registered for protocol
therapy.